Tito Fojo

Q: What Schools Are Affiliated With Tito Fojo

Tito Fojo is affiliated with the following schools: Johns Hopkins University, West Virginia University, Columbia University, University of California, San Francisco, University of Zurich, University of Arkansas, University of Arkansas for Medical Sciences, Kagoshima University, University of Lisbon, Institute of Cancer Research, University of California, Berkeley, Gyeongsang National University, MD Anderson Cancer Center

Tito Fojo's AcademicInfluence.com Rankings

Tito Fojo

Philosophy

#3831

World Rank

#6125

Historical Rank

Logic

#1440

World Rank

#2191

Historical Rank

philosophy Degrees

Tito Fojo

Biology

#4875

World Rank

#7216

Historical Rank

Biochemistry

#530

World Rank

#618

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Tito Fojo's Degrees

Doctorate Medicine University of Lisbon
PhD Biochemistry University of California, San Francisco

Why Is Tito Fojo Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Tito Fojo's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Multidrug resistance in cancer: role of ATP–dependent transporters (2002) (5064)
Tumour stem cells and drug resistance (2005) (3551)
Expression of a multidrug-resistance gene in human tumors and tissues. (1987) (1529)
GoMiner: a resource for biological interpretation of genomic and proteomic data (2003) (1271)
Expression of a multidrug resistance gene in human cancers. (1989) (1238)
An Information-Intensive Approach to the Molecular Pharmacology of Cancer (1997) (1134)
Revisiting the role of ABC transporters in multidrug-resistant cancer (2018) (976)
Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. (1999) (828)
The role of ABC transporters in clinical practice. (2003) (774)
Paclitaxel-resistant Human Ovarian Cancer Cells Have Mutant β-Tubulins That Exhibit Impaired Paclitaxel-driven Polymerization* (1997) (691)
Expression of the Multidrug Resistance Gene in Human Cancer (1991) (672)
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. (2009) (668)
Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. (1986) (668)
Delivering affordable cancer care in high-income countries. (2011) (656)
Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. (1996) (589)
Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification. (1986) (567)
Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. (2002) (540)
Isolation and genetic characterization of human KB cell lines resistant to multiple drugs (1985) (521)
Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. (2015) (496)
A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. (2000) (436)
Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines. (1985) (434)
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. (1996) (432)
Use of the polymerase chain reaction in the quantitation of mdr-1 gene expression. (1990) (428)
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. (2011) (426)
Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. (1997) (422)
Microtubule-interfering Agents Activate c-Jun N-terminal Kinase/Stress-activated Protein Kinase through Both Ras and Apoptosis Signal-regulating Kinase Pathways* (1998) (370)
p53 is associated with cellular microtubules and is transported to the nucleus by dynein (2000) (364)
Molecular effects of paclitaxel: Myths and reality (a critical review) (1999) (364)
Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. (1994) (356)
How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. (2009) (355)
Strategies for reversing drug resistance (2003) (348)
Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. (2012) (340)
p53 Inhibits Hypoxia-inducible Factor-stimulated Transcription* (1998) (300)
Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. (1988) (298)
Cancer drugs in the United States: Justum Pretium--the just price. (2013) (285)
Combination chemotherapy in advanced adrenocortical carcinoma. (2012) (275)
Mitosis is not a key target of microtubule agents in patient tumors (2011) (268)
Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. (1999) (266)
Expression of the multidrug-resistant gene in hepatocarcinogenesis and regenerating rat liver. (1987) (259)
Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases (2003) (257)
Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture. (2014) (247)
Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. (1990) (240)
EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. (1993) (240)
Cardiac Studies in Patients Treated with Depsipeptide, FK228, in a Phase II Trial for T-Cell Lymphoma (2006) (237)
Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity (2001) (234)
Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene. (1987) (226)
Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. (1994) (225)
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. (2005) (224)
Modulation of the expression of a multidrug resistance gene (mdr-1/P-glycoprotein) by differentiating agents. (1989) (220)
Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. (2002) (219)
Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen. (1995) (218)
Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics (2002) (210)
Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma (2015) (198)
Inhibitors Targeting Mitosis: Tales of How Great Drugs against a Promising Target Were Brought Down by a Flawed Rationale (2012) (198)
Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. (2007) (193)
Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies. (2012) (181)
Metallothionein gene expression and resistance to cisplatin in human ovarian cancer (1990) (179)
MicroRNA profiling of adrenocortical tumors reveals miR‐483 as a marker of malignancy (2011) (174)
Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. (2001) (173)
Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. (2007) (173)
Amplification of DNA sequences in human multidrug-resistant KB carcinoma cells. (1985) (172)
Bcl-xL is phosphorylated in malignant cells following microtubule disruption. (1998) (168)
Percutaneous tumor ablation with radiofrequency (2002) (168)
Expression of a drug resistance gene in human neuroblastoma cell lines: modulation by retinoic acid-induced differentiation (1989) (167)
P‐glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines (1991) (165)
Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. (1998) (165)
Precision oncology: origins, optimism, and potential. (2016) (158)
Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations. (2011) (158)
Multidrug resistance of DNA-mediated transformants is linked to transfer of the human mdr1 gene (1986) (153)
Steroid transport, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells (1996) (149)
A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer (2010) (145)
Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine (2008) (145)
Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)). (2008) (142)
Is Cell Death a Critical End Point for Anticancer Therapies or Is Cytostasis Sufficient? (2007) (142)
Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins (2015) (141)
68Ga-DOTATATE PET/CT in the Localization of Head and Neck Paragangliomas Compared with Other Functional Imaging Modalities and CT/MRI (2016) (138)
Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. (2003) (138)
Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. (2003) (133)
Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. (2009) (133)
Expression of the mdr-1/P-170 gene in patients with acute lymphoblastic leukemia. (1989) (132)
Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials. (2015) (132)
PET/CT comparing 68Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma (2016) (131)
HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. (2003) (131)
Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. (2010) (129)
The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy (2001) (127)
New syndrome of paraganglioma and somatostatinoma associated with polycythemia. (2013) (126)
Expression of the multidrug resistance, MDR1, gene in neuroblastomas. (1990) (124)
Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy (2010) (122)
Increased mdr-1/P-glycoprotein expression after treatment of human colon carcinoma cells with P-glycoprotein antagonists. (1993) (122)
A Serial Analysis of Gene Expression (SAGE) database analysis of chemosensitivity: comparing solid tumors with cell lines and comparing solid tumors from different tissue origins. (2004) (120)
Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. (2000) (120)
Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi. (1997) (120)
Current approaches and recent developments in the management of head and neck paragangliomas. (2014) (117)
Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. (1995) (116)
Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR). (2005) (116)
Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs. (2000) (115)
Biologically Targeted Cancer Therapy and Marginal Benefits: Are We Making Too Much of Too Little or Are We Achieving Too Little by Giving Too Much? (2010) (114)
The evidence framework for precision cancer medicine (2018) (107)
Reversal of multidrug resistance. (1994) (107)
Gene rearrangement: a novel mechanism for MDR-1 gene activation. (1997) (106)
Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. (2011) (105)
Tubulin/microtubules: still a promising target for new chemotherapeutic agents. (2000) (105)
Do patient access schemes for high-cost cancer drugs deliver value to society?—lessons from the NHS Cancer Drugs Fund (2017) (102)
False-negative ¹²³I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease. (2012) (102)
The role of microtubules in cell biology, neurobiology, and oncology / (2008) (101)
Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells. (1998) (101)
A Phase I Study of the P-Glycoprotein Antagonist Tariquidar in Combination with Vinorelbine (2009) (100)
Amplification of 4q21–q22 and the MXR gene in independently derived mitoxantrone‐resistant cell lines (2000) (99)
Differential modulation of P-glycoprotein transport by protein kinase inhibition. (1993) (99)
Increased MDR1 Expression in Normal and Malignant Peripheral Blood Mononuclear Cells Obtained from Patients Receiving Depsipeptide (FR901228, FK228, NSC630176) (2006) (99)
Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: A possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition (2008) (95)
Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents. (2001) (95)
Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications. (1993) (94)
Enhanced adenovirus transgene expression in malignant cells treated with the histone deacetylase inhibitor FR901228. (2001) (91)
Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas. (1991) (90)
Various methods of analysis of mdr-1/P-glycoprotein in human colon cancer cell lines. (1992) (89)
Localization of multidrug resistance-associated DNA sequences to human chromosome 7 (1986) (89)
Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors. (2005) (88)
Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data. (2008) (87)
CHARACTERISTICS AND OUTCOMES OF METASTATIC SDHB AND SPORADIC PHEOCHROMOCYTOMA/PARAGANGLIOMA: AN NATIONAL INSTITUTES OF HEALTH STUDY. (2016) (85)
A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma (2002) (84)
Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833. (2001) (84)
Radiofrequency ablation: a novel approach for treatment of metastatic pheochromocytoma. (2001) (83)
MiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors. (2013) (83)
Modulation of P-glycoprotein phosphorylation and drug transport by sodium butyrate. (1992) (82)
Operative management for recurrent and metastatic adrenocortical carcinoma (2012) (82)
Conservation of the Class I -Tubulin Gene in Human Populations and Lack of Mutations in Lung Cancers and Paclitaxel-resistant Ovarian Cancers 1 (2002) (81)
Multidrug resistance in ovarian cancer (1987) (81)
A Phase I clinical trial of ixabepilone (BMS‐247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days (2005) (80)
Cytogenetic and molecular characterization of random chromosomal rearrangements activating the drug resistance gene, MDR1/P‐glycoprotein, in drug‐selected cell lines and patients with drug refractory ALL (1998) (77)
Mitogen-activated protein kinase pathway is dispensable for microtubule-active drug-induced Raf-1/Bcl-2 phosphorylation and apoptosis in leukemia cells (1999) (76)
Colorectal Cancer Survival Gains and Novel Treatment Regimens: A Systematic Review and Analysis. (2015) (76)
A Phase I study of infusional vinblastine in combination with the p‐glycoprotein antagonist PSC 833 (valspodar) (2001) (74)
The clinical development of new mitotic inhibitors that stabilize the microtubule. (2004) (73)
Reversal of multidrug resistance: lessons from clinical oncology. (2002) (73)
Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage. (2008) (73)
Cancer, DNA repair mechanisms, and resistance to chemotherapy. (2001) (71)
The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer. (2014) (71)
Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T‐cell lymphoma (2010) (70)
Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer (2000) (69)
A Phase I/II Study of Infusional Vinblastine with the P-Glycoprotein Antagonist Valspodar (PSC 833) in Renal Cell Carcinoma (2004) (67)
Mechanisms of resistance to PARP inhibitors--three and counting. (2013) (65)
Identification of Non–Small Cell Lung Cancer Sensitive to Systemic Cancer Therapies Using Radiomics (2020) (65)
Paclitaxel (Taxol(R)) inhibits motility of paclitaxel-resistant human ovarian carcinoma cells. (1996) (64)
Adjuvant mitotane for adrenocortical cancer--a recurring controversy. (2008) (64)
Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck. (2018) (63)
bcl-2 protein downregulation is not required for differentiation of multidrug resistant HL60 leukemia cells. (1996) (63)
Progression-Free Survival Is Simply a Measure of a Drug’s Effect While Administered and Is Not a Surrogate for Overall Survival (2009) (60)
Contribution of glutathione and glutathione‐dependent enzymes in the reversal of adriamycin resistance in colon carcinoma cell lines (1991) (59)
Accompanying protein alterations in malignant cells with a microtubule-polymerizing drug-resistance phenotype and a primary resistance mechanism. (2001) (59)
The role of efflux pumps in drug-resistant metastatic breast cancer: new insights and treatment strategies. (2007) (58)
Steroid treatment, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells. (1996) (58)
The histone deacetylase inhibitor FK228 preferentially enhances adenovirus transgene expression in malignant cells. (2003) (58)
Inhibition of Transcription Results in Accumulation of Wt p53 Followed by Delayed Outburst of p53-Inducible Proteins: p53 as a Sensor of Transcriptional Integrity (2002) (58)
Future perspectives for the development of P-glycoprotein modulators. (1998) (58)
An Appraisal of Clinically Meaningful Outcomes Guidelines for Oncology Clinical Trials. (2016) (57)
Platinums: Extending Their Therapeutic Spectrum (2004) (57)
Combinations of pacliataxel and vinblastine and their effects on tublin polymerization and cellular cytotoxicity: Characterization of a synergistic schedule (1998) (57)
Tumor Cells Resistant to a Microtubule-Depolymerizing Hemiasterlin Analogue, HTI-286, Have Mutations in α- or β-Tubulin and Increased Microtubule Stability (2004) (57)
Epothilones: a novel class of non-taxane microtubule-stabilizing agents. (2002) (56)
Cancer economics, policy and politics: What informs the debate? Perspectives from the EU, Canada and US (2014) (56)
Is there room for improvement in adverse event reporting in the era of targeted therapies? (2008) (56)
Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers (2013) (56)
Multidrug resistance: P-glycoprotein and its allies--the elusive foes. (1989) (56)
Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth (2012) (56)
Cellular control of human multidrug resistance 1 (mdr-1) gene expression in absence and presence of gene amplification in human cancer cells. (1994) (56)
Liver Resection and Ablation for Metastatic Adrenocortical Carcinoma (2011) (55)
Intractable cancers: the many faces of multidrug resistance and the many targets it presents for therapeutic attack. (2004) (54)
Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas. (1995) (54)
Commentary: Novel therapies for cancer: why dirty might be better. (2008) (54)
Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome. (2016) (54)
Cellular adaptation to drug exposure: evolution of the drug-resistant phenotype. (1997) (54)
Sorafenib-induced eruptive melanocytic lesions. (2008) (53)
Using the national cancer institute anticancer drug screen to assess the effect of MRP expression on drug sensitivity profiles. (1998) (52)
Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients. (2014) (52)
Why do phase III clinical trials in oncology fail so often? (2012) (52)
Loss of cell cycle control allows selective microtubule-active drug-induced Bcl-2 phosphorylation and cytotoxicity in autonomous cancer cells. (2000) (52)
Characterization of Gene Rearrangements Leading to Activation of MDR-1*> (2006) (52)
Romidepsin in peripheral and cutaneous T‐cell lymphoma: mechanistic implications from clinical and correlative data (2015) (52)
Epidemiologic trends in neuroendocrine tumors: An examination of incidence rates and survival of specific patient subgroups over the past 20 years. (2018) (51)
SDHB-related pheochromocytoma and paraganglioma penetrance and genotype–phenotype correlations (2017) (51)
Efflux of Rhodamine From CD56+ Cells as a Surrogate Marker for Reversal of P-Glycoprotein–Mediated Drug Efflux by PSC 833 (1999) (51)
Inhibitors of transcription, proteasome inhibitors, and DNA-damaging drugs differentially affect feedback of p53 degradation. (1998) (51)
p53 as a therapeutic target: unresolved issues on the road to cancer therapy targeting mutant p53. (2002) (50)
Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance. (1997) (49)
Pulmonary resection for metastatic adrenocortical carcinoma: the National Cancer Institute experience. (2011) (49)
A phase II trial of gefitinib monotherapy in patients with unresectable adrenocortical carcinoma (ACC) (2007) (48)
Identification of non-cross-resistant platinum compounds with novel cytotoxicity profiles using the NCI anticancer drug screen and clustered image map visualizations. (2005) (48)
Challenges of Evaluating the Cardiac Effects of Anticancer Agents (2006) (48)
External Beam Radiation Therapy in Treatment of Malignant Pheochromocytoma and Paraganglioma (2014) (47)
Enhancement of aqueous solubility and stability employing a trans acetate axis in trans planar amine platinum compounds while maintaining the biological profile. (2005) (47)
Genetic and epigenetic modeling of the origins of multidrug-resistant cells in a human sarcoma cell line. (2005) (46)
Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis. (2017) (45)
Efflux of rhodamine from CD56+ cells as a surrogate marker for reversal of P-glycoprotein-mediated drug efflux by PSC 833. (1999) (45)
Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers. (2002) (45)
A peptide inhibitor derived from p55PIK phosphatidylinositol 3-kinase regulatory subunit: a novel cancer therapy (2008) (43)
The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study (2014) (43)
CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib. (2017) (43)
Paclitaxel-Induced FasL-Independent Apoptosis and Slow (Non-Apoptotic) Cell Death (2002) (43)
Radiofrequency ablation of metastatic pheochromocytoma. (2009) (43)
Histone deacetylase inhibitor FR901228 enhances adenovirus infection of hematopoietic cells. (2002) (42)
Respiratory cryptosporidiosis in a patient with malignant lymphoma. Report of a case and review of the literature. (1990) (41)
Mechanisms of resistance to cisplatin and alkylating agents. (1989) (40)
A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumors. (2012) (40)
Ex Vivo Rapamycin Generates Apoptosis-Resistant Donor Th2 Cells That Persist In Vivo and Prevent Hemopoietic Stem Cell Graft Rejection1 (2008) (39)
Mediastinal paragangliomas: association with mutations in the succinate dehydrogenase genes and aggressive behavior. (2008) (39)
The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel. (2001) (38)
An ATP-binding cassette gene (ABCG3) closely related to the multidrug transporter ABCG2 (MXR/ABCP) has an unusual ATP-binding domain (2001) (38)
The Histone Deacetylase Inhibitor FR901228 (Depsipeptide) Restores Expression and Function of Pseudo-Null p53 (2002) (37)
Transactivation of the metallothionein promoter in cisplatin-resistant cancer cells: a specific gene therapy strategy. (2000) (37)
A Phase II Clinical Trial of Ixabepilone (Ixempra; BMS-247550; NSC 710428), an Epothilone B Analog, in Patients with Metastatic Renal Cell Carcinoma (2010) (37)
Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin. (2004) (37)
Update of the NCI multiinstitutional phase II trial of romidepsin, FK228, for patients with cutaneous or peripheral T-cell lymphoma (2007) (36)
Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma (2013) (36)
Resistance to paclitaxel mediated by P-glycoprotein can be modulated by changes in the schedule of administration (1997) (35)
Clinical Reversal of Multidrug Resistance (1996) (35)
Expression of a 95 kDa membrane protein is associated with low daunorubicin accumulation in leukaemic blast cells. (1995) (34)
Hazard ratios in cancer clinical trials—a primer (2012) (33)
Assessing the Eventual Publication of Clinical Trial Abstracts Submitted to a Large Annual Oncology Meeting. (2016) (32)
Inhibiting mitochondrial respiration prevents cancer in a mouse model of Li-Fraumeni syndrome (2016) (32)
Breast implant‐associated anaplastic large cell lymphoma in a patient with Li–Fraumeni syndrome (2015) (32)
Inhibition of HIF-1- and wild-type p53-stimulated transcription by codon Arg175 p53 mutants with selective loss of functions. (2001) (32)
Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysis (2017) (32)
Progress and Opportunities to Advance Clinical Cancer Therapeutics Using Tumor Dynamic Models (2019) (31)
Role of Radiotherapy in Adrenocortical Carcinoma (2013) (31)
Microtubule-disrupting chemotherapeutics result in enhanced proteasome-mediated degradation and disappearance of tubulin in neural cells. (2010) (30)
BEZ235: When Promising Science Meets Clinical Reality (2016) (30)
Functional Imaging Signature of Patients Presenting with Polycythemia/Paraganglioma Syndromes (2017) (30)
A phase II clinical trial of BMS-247550 (ixabepilone), a microtubule-stabilizing agent in renal cell cancer. (2004) (30)
Interleukin‐13 receptor alpha2 is a novel therapeutic target for human adrenocortical carcinoma (2012) (29)
Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung (2018) (29)
A translational study of ixabepilone (BMS-247550) in renal cell cancer (RCC): Assessment of its activity and demonstration of target engagement in tumor cells (2005) (29)
Why RECIST works and why it should stay--counterpoint. (2012) (29)
Phase I trial of romidepsin, a histone deacetylase inhibitor, given on days one, three and five in patients with thyroid and other advanced cancers (2008) (28)
TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer (2016) (28)
Limitations of differential display. (1998) (28)
Construction of gene therapy vectors targeting thyroid cells: enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the cyclic adenosine 3',5'-monophosphate pathway and demonstration of activity in follicular and anaplastic thyroid carcinoma cells. (2001) (28)
Increased 99 mTc-Sestamibi Accumulation in Normal Liver and Drug-resistant Tumors after the Administration of the Glycoprotein Inhibitor , XR 9576 (2003) (28)
The histone deacetylase inhibitor FK228 given prior to adenovirus infection can boost infection in melanoma xenograft model systems (2007) (27)
Continuing a Cancer Treatment Despite Tumor Growth May Be Valuable: Sunitinib in Renal Cell Carcinoma as Example (2014) (26)
The role of MDR-1 in refractory lymphoma. (1997) (26)
Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability. (2004) (25)
Evidence for Microtubule Target Engagement in Tumors of Patients Receiving Ixabepilone (2007) (25)
Practical considerations in the evaluation and management of adrenocortical cancer. (2010) (25)
Aberrant transcription from an unrelated promoter can result in MDR-1 expression following drug selection in vitro and in relapsed lymphoma samples. (2005) (24)
The Role of Wild-Type p53 in Cisplatin-Induced Chk2 Phosphorylation and the Inhibition of Platinum Resistance with a Chk2 Inhibitor (2010) (24)
Synthesis and Biological Evaluation of 12,13‐Cyclopropyl and 12,13‐Cyclobutyl Epothilones (2001) (24)
Implantation of recombinant rat myocytes into adult skeletal muscle: a potential gene therapy. (1991) (24)
Molecular targets in the National Cancer Institute drug screen (1995) (24)
Adenovirus HSV‐TK construct with thyroid‐specific promoter: Enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the camp pathway (2002) (22)
Oligomerization of p53 Precedes its Association with Dynein and Nuclear Accumulation (2006) (22)
Anticancer Agents from Unique Natural Products Sources (2003) (22)
Impaired p53 binding to importin: a novel mechanism of cytoplasmic sequestration identified in oxaliplatin-resistant cells (2009) (22)
Development of Gene Ontology Tool for Biological Interpretation of Genomic and Proteomic Data (2003) (22)
Microtubule Targeting Agents (2010) (22)
Discodermolide: just another microtubule-stabilizing agent? No! A lesson in synergy. (2000) (21)
ANG1005 for breast cancer brain metastases: correlation between 18F-FLT–PET after first cycle and MRI in response assessment (2016) (21)
Succinate dehydrogenase gene mutations in cardiac paragangliomas. (2015) (21)
Potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer. (2012) (21)
Initial Pharmacokinetics and Bioavailability of PSC 833, a P‐Glycoprotein Antagonist (1997) (21)
Cisplatin versus cetuximab with definitive concurrent radiotherapy for head and neck squamous cell carcinoma: An analysis of Veterans Health Affairs data (2018) (21)
Price, value, and the cost of cancer drugs. (2016) (20)
Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide. (1996) (20)
Precision oncology: a strategy we were not ready to deploy. (2016) (20)
Screening of cancer tissue arrays identifies CXCR4 on adrenocortical carcinoma: correlates with expression and quantification on metastases using 64Cu-plerixafor PET (2017) (20)
Increased uptake of [¹²³I]meta-iodobenzylguanidine, [¹⁸F]fluorodopamine, and [³H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors. (2011) (20)
Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors. (2009) (20)
Expression of the Multidrug Resistance-Associated Protein Gene in Refractory Lymphoma: Quantitation by a Validated Polymerase Chain Reaction Assay (1997) (20)
Phase II clinical trial of axitinib in metastatic pheochromocytomas and paraganlgiomas (P/PG): Preliminary results. (2015) (19)
Long-acting somatostatin analogues in the treatment of unresectable/metastatic neuroendocrine tumors. (2017) (19)
Emerging Therapeutic Implications of STK11 Mutation: Case Series. (2020) (19)
Clinical trial results: a clinical trial bazaar! (2014) (19)
Treatment of metastatic disease in patients with neuroendocrine tumors. (2006) (19)
Increased MDR 1 Expression in Normal andMalignant Peripheral BloodMononuclear Cells Obtained from Patients Receiving Depsipeptide ( FR 901228 , FK 228 , NSC 630176 ) (2006) (18)
Phase II trial of thalidomide (T), bevacizumab (Bv), and docetaxel (Doc) in patients (pts) with metastatic castration-refractory prostate cancer (mCRPC) (2008) (18)
Radiofrequency ablation for tumor-related massive hematuria. (2005) (17)
Continued Tumor Reduction of Metastatic Pheochromocytoma/Paraganglioma Harboring Succinate Dehydrogenase Subunit B Mutations with Cyclical Chemotherapy (2018) (17)
Expression of the multidrug resistance-associated protein gene in refractory lymphoma: quantitation by a validated polymerase chain reaction assay. (1997) (17)
Immune Status and Associated Mortality After Cancer Treatment Among Individuals With HIV in the Antiretroviral Therapy Era. (2019) (17)
Adrenocortical Cancer: A Molecularly Complex Disease Where Surgery Matters (2016) (17)
Epidermal Growth Factor Receptor Inhibitors: A Moving Target? (2005) (17)
Bevacizumab and breast cancer: the E2100 outlier. (2010) (17)
First in human phase 1/2a study of PEN-221 somatostatin analog (SSA)-DM1 conjugate for patients (PTS) with advanced neuroendocrine tumor (NET) or small cell lung cancer (SCLC): Phase 1 results. (2018) (17)
Mathematical Modeling of “Chronic” Infectious Diseases: Unpacking the Black Box (2017) (16)
Measurement of Current Substance Use in a Cohort of HIV-Infected Persons in Continuity HIV Care, 2007–2015 (2018) (16)
Drug resistance in adult lymphomas. (1994) (16)
Non-inferiority trials: why oncologists must remain wary. (2015) (16)
Clinical reversal of multidrug resistance. (1996) (16)
Brain metastasis in patients with adrenocortical carcinoma: a clinical series. (2015) (15)
Current and future trends in tuberculosis incidence in New York City: a dynamic modelling analysis. (2017) (15)
Retained platinum uptake and indifference to p53 status make novel transplatinum agents active in platinum-resistant cells compared to cisplatin and oxaliplatin (2012) (15)
Stable Disease Is Not Preferentially Observed With Targeted Therapies and as Currently Defined Has Limited Value in Drug Development (2009) (15)
Phase I/II trial of crolibulin and cisplatin in solid tumors with a focus on anaplastic thyroid cancer: Phase I results. (2013) (15)
Successful chemotherapy of hepatic metastases in a case of succinate dehydrogenase subunit B-related paraganglioma (2009) (15)
Adjuvant and neoadjuvant cancer therapies: A historical review and a rational approach to understand outcomes. (2019) (15)
Construction of gene therapy vectors targeting adrenocortical cells: enhancement of activity and specificity with agents modulating the cyclic adenosine 3',5'-monophosphate pathway. (2000) (15)
Do Symptoms of Depression Interact with Substance Use to Affect HIV Continuum of Care Outcomes? (2018) (14)
KB Carcinoma Cell Lines Reduced Drug Accumulation in Multiply Drug-resistant Human (2006) (14)
Molecular biology of drug resistance (1987) (14)
Comparison by Race of Conservative Management for Low-Risk and Intermediate-Risk Prostate Cancers in Veterans From 2004 to 2018 (2020) (13)
Expression of Drug Resistance Genes in VP‐16 and mAMSA‐selected Human Carcinoma Cells (2001) (13)
ABC Transporters: Involvement in Multidrug Resistance and Drug Disposition (2014) (13)
Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer (2018) (12)
Incidence of Mutation and Deletion in Topoisomerase IIα mRNA of Etoposide and mAMSA–resistant Cell Lines (2001) (12)
Treatment of recurrent cervical adenocarcinoma with BMS-247550, an epothilone B analog. (2003) (12)
Metastatic and recurrent adrenocortical cancer is not defined by its genomic landscape (2020) (12)
Taxanes and other microtubule stabilizing agents. (1999) (12)
Are patients with hormonally functional phaeochromocytoma and paraganglioma initially receiving a proper adrenoceptor blockade? A retrospective cohort study (2016) (12)
R-Loop–Mediated ssDNA Breaks Accumulate Following Short-Term Exposure to the HDAC Inhibitor Romidepsin (2021) (12)
Differential expression of cell adhesion genes: Implications for drug resistance (2005) (11)
Recent Substance Use and Probability of Unsuppressed HIV Viral Load among Persons on Antiretroviral Therapy in Continuity Care. (2019) (11)
Reply to ‘H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines’ (2019) (11)
Multiplying therapies and reducing toxicity in metastatic melanoma (2015) (10)
A phase 2 trial of BMS-247550 (ixabepilone), an epothilone B analog, given daily x 5 in breast cancer. (2004) (10)
Phase II Clinical Trial of Ixabepilone in Metastatic Cervical Carcinoma. (2014) (10)
Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure. (2001) (10)
Effects of acetylation and guanidination on alkaline conformations of chymotrypsin. (1983) (10)
Resiniferatoxin, a potent TRPV1 agonist: Intrathecal administration to treat severe pain associated with advanced cancer—case report (2010) (10)
Tubulin from paclitaxel-resistant cells as a probe for novel antimicrotubule agents (1997) (10)
Like p53, the proliferation-associated protein p120 accumulates in human cancer cells following exposure to anticancer drugs. (1998) (10)
Complementation of two mutant p53: Implications for loss of heterozygosity in cancer (2005) (10)
Depletion of Mutant p 53 and Cytotoxicity of Histone Deacetylase Inhibitors (2005) (10)
A precision medicine approach for psychiatric disease based on repeated symptom scores. (2017) (10)
Reversal of multidrug resistance. (1994) (9)
Arsenic Trioxide: Still a Mystery (2002) (9)
Female fertility following dose-adjusted EPOCH-R chemotherapy in primary mediastinal B-cell lymphomas (2016) (9)
A novel approach to assess real-world efficacy of cancer therapy in metastatic prostate cancer. Analysis of national data on Veterans treated with abiraterone and enzalutamide. (2019) (9)
High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses (2015) (9)
Phase II Trial of Romidepsin, FK228, in Cutaneous and Peripheral T-Cell Lymphoma: Clinical Activity and Molecular Markers. (2006) (9)
The extent of chromosomal aberrations induced by chemotherapy in non-human primates depends on the schedule of administration. (2005) (8)
Unbiased Assessment of H-STS cells as high-fidelity models for gastro-enteropancreatic neuroendocrine tumor drug mechanism of action analysis (2019) (8)
Tariquidar (XR9576) is a potent and effective P-glycoprotein (Pgp) inhibitor that can be administered safely with chemotherapy (2005) (8)
Ixabepilone (BMS-247550) and metastatic renal cell carcinoma (mRCC) (2008) (8)
Phase I trial of the epothilone B analog BMS-247550 (ixabepilone) in children with refractory solid tumors (2005) (8)
Hypophosphorylation of Topoisomerase IIα in Etoposide (VP‐16)‐resistant Human Carcinoma Cell Lines Associated with Carboxy‐terminal Truncation (2001) (7)
with the histone deacetylase inhibitors (2010) (7)
A novel 95 kilodalton membrane polypeptide associated with lung cancer drug resistance (1993) (7)
Clinical trials: New drug for pancreatic cancer highlights the dual effect of regulatory approvals (2016) (7)
Desperation Oncology. (2018) (7)
Response: Re: How Much Is Life Worth: Cetuximab, Non–Small Cell Lung Cancer, and the $440 Billion Question (2010) (7)
Tales of How Great Drugs Were Brought Down by a Flawed Rationale—Response (2013) (7)
Pituitary homeobox factor 1, a novel transcription factor in the adrenal regulating steroid 11beta-hydroxylase. (2003) (7)
Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation (2020) (6)
Anti-Hu paraneoplastic brainstem encephalitis caused by a pancreatic neuroendocrine tumor presenting with central hypoventilation (2017) (6)
Antiangiogenic (AG) Synergy with Ixabepilone (IXA): Translation of Preclinical Studies to the Clinical Setting. (2009) (6)
A database study that identifies genes whose expression correlates, negatively or positively, with 5-year survival of cancer patients. (2007) (6)
Arsenic trioxide (As(2)O(3)): still a mystery. (2002) (6)
Novel Tumor Growth Rate Analysis in the Randomized CLARINET Study Establishes the Efficacy of Lanreotide Depot/Autogel 120 mg with Prolonged Administration in Indolent Neuroendocrine Tumors (2021) (6)
The Effect Of Buprenorphine On HIV Viral Suppression. (2021) (6)
Multidrug-resistant tuberculosis in India: looking back, thinking ahead. (2017) (6)
Therapies with diverse mechanisms of action kill cells by a similar exponential process in advanced cancers. (2014) (6)
Depression and HIV viral non-suppression among people engaged in HIV care in an urban clinic, 2014-2019. (2021) (6)
Taccalonolides: A microtubule stabilizer poses a new puzzle with old pieces (2011) (5)
Inappropriate censoring in Kaplan-Meier analyses. (2021) (5)
Acetyl-L-carnitine and prevention of chemotherapy-induced peripheral neuropathy: can anything work? (2013) (5)
Effect of glycerol on protein acetylation by acetic anhydride. (1985) (5)
Wild-type p53 marginally induces endogenous MDR-1 mRNA without causing a measurable drug resistance in human cancer cells. (2001) (5)
Changing Patterns of Alcohol Use and Probability of Unsuppressed Viral Load Among Treated Patients with HIV Engaged in Routine Care in the United States (2020) (5)
Symptom screen: diagnostic usefulness in detecting pulmonary tuberculosis in HIV-infected pregnant women in Kenya. (2011) (5)
Effect of sunitinib (SU) administration on post-treatment survival in patients with metastatic renal cell carcinoma (mRCC) treated on the upfront randomized phase III trial of sunitinib or interferon alfa (IFN). (2011) (4)
Pancreatic cancer: Targeting KRAS and the vitamin D receptor via microtubules (2015) (4)
Multidrug resistance due to P-glycoprotein. (1990) (4)
A phase II study of a yeast-based therapeutic cancer vaccine, GI-6207, targeting CEA in patients with minimally symptomatic, metastatic medullary thyroid cancer. (2013) (4)
Neutral evolution of drug resistant colorectal cancer cell populations is independent of their KRAS status (2017) (4)
Kinetic analysis of breast tumor decay and growth following ixabepilone plus capecitabine (IXA + CAP) versus capecitabine alone (CAP) to discern whether the superiority of the combination is a result of slower growth, enhanced tumor cell kill, or both. (2010) (4)
Effects of the P-glycoprotein (Pgp) antagonist tariquidar (XR-9576; TQD) on Pgp function as well as the toxicity and efficacy of combined chemotherapy in patients with metastatic adrenocortical cancer (mACC) (2008) (4)
Can Mutations in γ-Actin Modulate the Toxicity of Microtubule Targeting Agents? (2006) (4)
Renal cell carcinoma: trying but failing to improve the only curative therapy. (2013) (4)
ABC Transport Genes in Mitoxantrone-resistant Cells : Demonstration of Homology Molecular Cloning of cDNAs Which Are Highly Overexpressed (1998) (4)
A retrospective analysis of intramural NCI prostate cancer trials: Progress made and insights gleaned. (2010) (4)
Cancer therapies and the problem of me too many. (2017) (4)
Distribution of cancer genes in human chromosomes. (2020) (4)
Modulation of multidrug resistance by dexverapamil in EPOCH-refractory lymphomas (2006) (4)
Phase I/II trial of vandetanib and bortezomib in adults with locally advanced or metastatic medullary thyroid cancer: Phase I results. (2011) (4)
Pilot Study Assessing Tolerability and Metabolic Effects of Metformin in Patients With Li-Fraumeni Syndrome. (2020) (3)
A Phase II Multi‐Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma (2017) (3)
[Expression of ATP binding cassette superfamily (multidrug resistance-1, multidrug resistance-associated protein, human canalicular multispecific organ anion transporter) mRNA in etoposide and m-AMSA resistant cell lines]. (1997) (3)
Use of a 90-Minute Admission Window and Front-Fill System to Reduce Work Compression on a General Medicine Inpatient Teaching Service. (2017) (3)
An imaging signature to predict outcome in metastatic colorectal cancer using routine computed tomography scans (2021) (3)
Study On The Fertility Status Of Females With Primary Mediastinal B-Cell Lymphoma Following Treatment With Dose-Adjusted EPOCH-Rituximab (2013) (3)
CHK2 and ERCC1 in the DNA Adduct Repair Pathway that Mediates Acquired Cisplatin Resistance (2009) (3)
RECIST: no longer the sharpest tool in the oncology clinical trials toolbox--reply to point. (2012) (3)
ANG1005 for brain metastases from breast cancer: 18F-FLT-PET and MRI as complementary approaches to response assessment. (2015) (3)
Multidrug resistance in human tumors. (1989) (3)
Delivering Affordable Cancer Care in High-income Countries: a Lancet Oncology Commission (2011) (3)
Multidrug resistance. (1991) (3)
Role of radiomics to differentiate benign from malignant pheochromocytomas and paragangliomas on contrast enhanced CT scans. (2019) (3)
Difference between duration of treatment (DOT) and progression-free survival (PFS) as a marker of un (2012) (3)
The rate of tumor growth during treatment accurately predicts the FDA gold standard of overall survival [OS] in a broad range of malignancies. (2018) (3)
Unusual locations of involvement by malignancies: Case 2. Metastatic pheochromocytoma to the colon. (2003) (3)
Long‐term outcomes in patients with advanced adrenocortical carcinoma after image‐guided locoregional ablation or embolization (2021) (3)
Accumulation of novel transplatinum complexes in cisplatin and oxaliplatin resistant cell lines overcomes resistance (2005) (3)
Decade in review—funding in cancer research: National Cancer Institute awards—a work in progress (2014) (3)
Abstract No. 12: Radiofrequency Ablation for Metastatic Pheochromocytoma: Safety, Clinical Efficacy and Hemodynamic Management (2009) (3)
High efficacy and continued tumor shrinkage with cyclophosphamide, vincristine, and dacarbazine (CVD) in patients (Pts) with malignant pheochromocytoma/paraganglioma harboring succinate dehydrogenase subunit B (SDHB) mutations. (2011) (3)
Abstract 29: Design of a phase I chemoprevention study of metformin and Li-Fraumeni syndrome (LFS) (2014) (2)
Relationship of the emergence of KRAS mutations and resistance to panitumumab in second-line treatment of colorectal cancer (CRC). (2013) (2)
Overview of mechanisms of chemoresistance in ovarian cancer (2021) (2)
Studies of drug resistance in malignant lymphoma (1993) (2)
Can mutations in gamma-actin modulate the toxicity of microtubule targeting agents? (2006) (2)
Baseline radiomic signature to estimate overall survival in patients with non-small cell lung cancer. (2023) (2)
GnrH-agonist co-treatment during chemotherapy for the preservation of ovarian function: a meta-analysis (2014) (2)
Immunotherapy for adrenocortical cancer. (2019) (2)
Authors' reply: (Not) too early to say, “no targeting of mitosis!” (2011) (2)
NSC 710428 ) , an Epothilone B Analog , in Patients with Metastatic Renal Cell Carcinoma (2010) (2)
[Incidence of mutation and deletion in topoisomerase II mRNA of etoposide and m-AMSA resistant cell lines]. (1998) (2)
Cancer medicines on the WHO Model List of Essential Medicines: processes, challenges, and a way forward. (2022) (2)
Phase II clinical trial of bevacizumab plus ixabepilone in renal cell carcinoma. (2014) (2)
Microtubule Stabilizing Agents (2008) (2)
Cisplatin (CIS) versus cetuximab (CET) with definitive concurrent radiotherapy (RT) for head and neck squamous cell carcinoma (HNSCC): An analysis of veteran’s health data. (2018) (2)
Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in veterans. (2021) (2)
Chemotherapy drug resistance — a panel discussion (1987) (2)
Phase I trial of belinostat in combination with cisplatin (Cis) and etoposide (Etop). (2013) (2)
Twenty years of chemotherapy for colorectal cancer (CRC): Progress made, insights gleaned. (2012) (2)
Continuation of sunitinib following RECIST progression on first-line sunitinib. (2013) (2)
Drug resistant cells with very large proliferative potential grow exponentially in metastatic prostate cancer (2021) (2)
The high cost of ignorance in oncology. (2016) (2)
Drug Resistance In The Treatment of Cancer: The MDR genes (1998) (2)
Ending the Human Immunodeficiency Virus Epidemic: Towards an Evidence-Based Approach (2019) (2)
Pediatric phase I trial and pharmacokinetic study of P-glycoprotein inhibitor, tariquidar, in combination with doxorubicin, vinorelbine or docetaxel (2004) (2)
[Expression of DNA topoisomerases (I, II alpha, II beta) mRNA in etoposide- and mAMSA-resistant cell lines]. (1997) (2)
16 – Expression, Amplification, and Transfer of DNA Sequences Associated with Multidrug Resistance (1988) (2)
A randomized phase II clinical trial of enzalutamide in combination with the therapeutic cancer vaccine, PSA tricom, in metastatic, castration resistant prostate cancer. (2013) (2)
Effect of chemotherapy on the progress in colorectal cancer survival in the past two decades. (2014) (1)
Correlation between innate cytokine levels and progression in men with biochemically recurrent prostate cancer treated with intermittent hormonal therapy. (2019) (1)
Moving a pioneer journal into the future. (2016) (1)
Effect of metformin chemoprevention on metabolomics profiles in Li-Fraumeni Syndrome (LFS). (2017) (1)
Tumor regression and growth rates determined in two intramural NCI prostate cancer trials: The growth rate constant as an indicator of therapeutic efficacy. (2012) (1)
Design of placebo-controlled randomized trials of anticancer agents: Ethical considerations based on a review of published trials (2021) (1)
The Genomic Stability at the Coding Regions of the Multidrug Transporter Gene ABCB1: Insights into the Development of Alternative Drug Resistance Mechanisms in Human Leukemia Cells (2019) (1)
Targeted agents (TA) for advanced solid tumors (AST): What is the likelihood of being helped or harmed (LHH)? Assessing the clinical impact of therapies with FDA/EMEA approval. (2013) (1)
Gastrointestinal tumors, colorectal (2012) (1)
R-verapamil reverses drug resistance in some relapsed lymphoma patients: 165 (1994) (1)
The efficacy of combination chemotherapy with cisplatin and gemcitabine in patients with advanced adrenal cortical carcinoma (ACC). (2006) (1)
Pediatric phase I trial and pharmacokinetic study of P-glycoprotein inhibitor, tariquidar, in combination with doxorubicin, vinorelbine or docetaxel. (2004) (1)
Abstract P4-01-09: 18F-FLT-PET/CT for the prediction of response to ANG-1005 therapy in patients with brain metastases from breast cancer (2013) (1)
A novel analysis of data from the PALOMA-3 trial confirms the efficacy of palbociclib and provides an option for efficacy assessments that could accelerate drug approvals. (2022) (0)
Socioeconomic Factors, Urological Epidemiology and Practice Patterns Re: Delivering Affordable Cancer Care in High-Income Countries (2011) (0)
Abstract LB-003: OncoMatch: Unbiased, quantitative assessment of cancer model fidelity for drug sensitivity and mechanism of action elucidation (2020) (0)
Phase I T rial a nd P harmacokinetic S tudy o f B MS-247550, a n Epothilone B A nalog, A dministered I ntravenously o n a D aily Schedule f or F ive D ays (2003) (0)
Abstract B43: ANG1005, a novel brain-penetrant drug conjugate, in CNS metastases from breast cancer: FLT-PET imaging as a predictor of response (2015) (0)
Superiorityof [ 68 Ga ]-DOTATATEPET / CTtoOther Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma (2015) (0)
Inhibitors Targeting Mitosis (2013) (0)
The somatostatin receptor as a novel drug target in neuroendocrine prostate cancer (NEPC) (2020) (0)
Cuba Sí. Cancer No. (2018) (0)
Comparison of Demographics and Overall Survival (OS) Among Patients with Young-Onset(YO) and Late-Onset(LO) GI Neuroendocrine Tumors/Carcinomas (NETs/NECs) in the United States (2023) (0)
Diffusion of abiraterone use in prostate cancer patients. (2016) (0)
A comparison of cancer stage at diagnosis and treatment initiation between enrollees in an urban HIV clinic and SEER (2020) (0)
The histone deacetylase inhibitor FK228 can increase the levels of coxsackie-adenovirus receptor (CAR) in human xenografts in mouse model systems. (2004) (0)
Multidrug Resistance in Tissue Culture and Human Tissues (1989) (0)
Two decades of therapy in metastatic colorectal cancer (mCRC): An analysis to discern the contributi (2012) (0)
Molecular Oncology: Drug resistance: as complex and diverse as the disease itself (2013) (0)
Differences in five year survival after cancer diagnosis between HIV clinic enrollees and the general US population. (2020) (0)
Expression of a multidrug-resistance gene in human tumors and tissues ( cancer chemotherapy / doxorubicin / vinblastine ) (0)
Overall survival (OS) in gastrointestinal (GI) neuroendocrine tumors (NETs) based on primary site, stage, and surgery. (2023) (0)
111P Application of radiomics signatures and unidimensional vs volumetric measurement of early tumor growth dynamics (TGD) to predict first-line treatment outcomes in patients with stage IV non-small cell lung cancer (NSCLC) (2023) (0)
Comprar Microtubule Targets in Cancer Therapy | Fojo, Antonio T. | 9781588292940 | Springer (2007) (0)
Predictive Biomarkers and Personalized Medicine Analyzing thePivotal Trial ThatComparedSunitiniband IFNa in Renal Cell Carcinoma , Using a Method That Assesses Tumor Regression and Growth (2012) (0)
Abstract 765: Growth rates of tumors with numerous histologies remain constant while patients are on therapy (2012) (0)
Association of early tumor growth rate and survival outcomes in first-line metastatic non–small cell lung cancer (mNSCLC). (2022) (0)
Assessment and Comparison of Treatment Efficacy in Patients with Colorectal Cancer (CRC), Using a Novel Methodology to Estimate the Rate of Tumor Regression (D) and Growth (G) (2012) (0)
Oxaliplatin resistant cells possess a mutant p53 that is confined to the cytoplasm (2008) (0)
Determining the rate of tumor growth and decay in patients with metastatic breast cancer as an early efficacy endpoint: A study assessing ixabepilone efficacy. (2011) (0)
294. The Histone Deacetylase Inhibitor FK228 Increases Histone Acetylation, Coxsackie Adenovirus Receptor Levels and Adenovirus Transgene Expression in Human LOX IMVI Melanoma Xenografts (2006) (0)
Abstract 3527: A pharmacodynamic study of docetaxel in combination with the p-glycoprotein antagonist, tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer (2010) (0)
The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study (2014) (0)
453. The Histone Deacetylase Inhibitor FK228 Can Increase Adenovirus Transgene Protein Expression in Human LOX IMVI Melanoma Xenografts (2005) (0)
Influence of Cancer on COVID-19 Incidence, Outcomes, and Vaccine Effectiveness: A Prospective Cohort Study of U.S. Veterans (2022) (0)
Value of stable disease (SD) in drug development of targeted therapies (TGT). (2009) (0)
Clinical trial results: Sharing results, speeding discoveries. (2013) (0)
Cancer Progression and Tumor Growth Kinetics (2013) (0)
Early response metrics for predicting trial outcomes: A report from volumetric CT for precision analysis of clinical trials (Vol-PACT). (2018) (0)
Editor Columbia University Medical Center , Columbia University (2016) (0)
Reply to A. Berruti et al (2010) (0)
Book Review: Hematology–Oncology Therapy (2007) (0)
Correction: Continuing a cancer treatment despite tumor growth may be valuable: Sunitinib in renal cell carcinoma as example (2014) (0)
Using a program that computes tumor decay (d) and regrowth (g) rates and the fraction (Φ) of tumor killed to assist in clinical trials and improve patient survival. (2017) (0)
Detection of MDR1 alleles and acquired mutations as tools for understanding expression of MDR1 in drug selected cell lines and human cancers: 160 (1994) (0)
Acetylation Of Pronase Guanidine Stable Chymoelastase (1980) (0)
The genomic landscape of advanced gastrointestinal (GI) neuroendocrine tumors (NET) and carcinomas (NEC). (2023) (0)
Estimates of the rate of growth of lymph nodes measured volumetrically predicts survival in cutaneous T-cell lymphoma (CTCL) (2022) (0)
Using a Bayesian Approach to Predict Patients' Health and Response to Treatment (2020) (0)
Editor's Note ...Clinical Trial Reports: A New Section. (2012) (0)
Fish and CGH studies of gene rearrangement and amplification in drug resistance (1997) (0)
Comparative evaluation of commonly used antiemetics in the NCIs in vitro screen for antagonists of multidrug resistance (1995) (0)
The rate of tumor growth, g, as a biomarker for overall survival (OS) in prostate cancer (PC) in clinical trials as well as in real-world data from the Veterans Administration Medical Centers (VAMCs). (2019) (0)
Continued Tumor Reduction of Metastatic Pheochromocytoma/Paraganglioma Harboring Succinate Dehydrogenase Subunit B Mutations with Cyclical Chemotherapy (2018) (0)
The Role of Radiation Therapy in Adrenocortical Carcinoma (2012) (0)
Using tumor growth rate to inform treatment efficacy in pancreatic adenocarcinoma: From the metastatic to the neoadjuvant setting. (2023) (0)
Radiation Therapy in Management of Malignant Pheochromocytoma (2012) (0)
Epidermal Growth Factor Receptor Inhibitors : AMoving Target ? (2005) (0)
A Medical Pearl Harbor: Pandemic Uncovers Societal Fissures and Leadership Breaches (2021) (0)
Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regression Model to Pivotal Trial and Real-World Data. (2022) (0)
Abstract 2554: Copper transporter 2 (CTR2) is able to transport cisplatin and/or oxaliplatin in drug-resistant cell lines (2010) (0)
Correction: Screening of cancer tissue arrays identifies CXCR4 on adrenocortical carcinoma: correlates with expression and quantification on metastases using 64Cu-plerixafor PET (2018) (0)
Novel biomarkers in NSCLC: Radiomic analysis, kinetic analysis, and circulating tumor DNA. (2022) (0)
Tumor growth rate constants derived from data gathered while patients are on clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data (2007) (0)
Retrovirus-mediated gene transfer to myocytes. An approach to muscle gene therapy (1990) (0)
Early assessment of efficacy of ixabepilone (IXA) by analysis of the rate of tumor growth and decay using data from phase II and phase III clinical trials in metastatic breast cancer (MBC) patients (Pts). (2011) (0)
Expression of VEGF and N-cadherin in adrenal cortical cancers and a mouse xenograft model to assess possible new therapeutic targets (2007) (0)
The challenges of selecting cancer medicines for the WHO Essentials Medicines List with the elephant in the room: A path forward. (2023) (0)
Effect of bevacizumab (Bev) on the growth rate constants of renal carcinoma (RCC) tumors (2008) (0)
618. Coxsackie-Adenovirus Receptor (CAR) Levels Can Be Increased in Human Xenografts Followed by Treatment with FK228, a Histone Deacetylase Inhibitor (2004) (0)
Cancer Therapy: Clinical A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer (2011) (0)
Abstract 5152: Estimating the fraction of a tumor that is killed by a drug. (2013) (0)
Abstract LB-106: Microtubule-targeting agents (MTAs) disrupt intracellular trafficking of DNA repair proteins and augment the toxicity of DNA damaging agents (DDAs) (2014) (0)
A learning algorithm for predicting mental health symptoms and substance use. (2020) (0)
Pseudo-progressing to an unmet need. (2017) (0)
A method for assessing tumor response to therapy and more precisely guiding treatment decisions so a (2012) (0)
Introduction: chemotherapies in the treatment of breast cancer. (2005) (0)
Long‐term follow‐up experience with adjuvant therapy after irreversible electroporation of locally advanced pancreatic cancer (2022) (0)
Stem Cell Graft Rejection Persist In Vivo and Prevent Hemopoietic Apoptosis-Resistant Donor Th 2 Cells That Ex Vivo Rapamycin Generates (2007) (0)
Genomic stability at the coding regions of the multidrug transporter gene ABCB1: insights into the development of alternative drug resistance mechanisms in human leukemia cells (2020) (0)
A new approach for the treatment of adrenal cancer: Testing an adrenal-specific adenovirus suicide gene therapy vector in an adrenal cancer xenograft model system (2007) (0)
iodobenzylguanidine, [F]fluorodopamine, and [H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors (2011) (0)
Requirements for Meaningful Progress in the Therapy of Neuroendocrine Cancers. (2023) (0)
Adrenal Gland Carcinoma (1999) (0)
A novel method to assess drug efficacy in the real world finds benefit of olaparib in Veterans with prostate cancer whose tumors harbor BRCA2 mutations (2020) (0)
Tumor growth and regression rate constants from the CLARINET study as surrogate endpoints for progression free survival: A novel assessment approach in cancer therapy. (2018) (0)
Increased uptake of [ 23 I ] meta-iodobenzylguanidine , [ 18 F ] fluorodopamine , and [ 3 H ] norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors (2011) (0)
Revisiting the role of ABC transporters in multidrug-resistant cancer (2018) (0)
Alcohol Use Disorder and Recent Alcohol Use and HIV Viral Non-Suppression Among People Engaged in HIV Care in an Urban Clinic, 2014–2018 (2021) (0)
Abstract 4571: Autologous TARP peptide vaccination is associated with slowing in PSA velocity and a decrease in tumor growth rate in patients with Stage D0 prostate cancer. (2013) (0)
A novel approach to mine the Veterans Administration Informatics and Computing Infrastructure (VINCI) allows one to assess the efficacy of cancer therapies: Abiraterone and enzalutamide in Veterans with metastatic prostate cancer (PC). (2018) (0)
SESSION 2 : DRUG DELIVERY P 2 . 01 ANG-1005 in Patients with Brain Metastases from Breast Cancer : Correlative Imaging with 18 F-FLT-PET / CT (2015) (0)
Ending the HIV Epidemic: Towards an Evidence-Based Approach. (2019) (0)
From the guest editor: monitoring of therapeutic response to cancer treatment. (2009) (0)
1064PHigh-dose versus low-dose cisplatin with definitive concurrent radiotherapy for squamous cell carcinoma of the head and neck (SCC): An analysis of veteran’s health registry data (2017) (0)
Effect of treatment on the regression and growth rates of thymic epithelial tumors (TETs). (2015) (0)
Abstract CT156: Safety and tolerability of metformin for chemoprevention in Li-Fraumeni syndrome (LFS) (2016) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Tito Fojo?

Tito Fojo is affiliated with the following schools:

Tito Fojo's Academic­Influence.com Rankings

Tito Fojo's Degrees

Why Is Tito Fojo Influential?

Tito Fojo's Published Works

Published Works

What Schools Are Affiliated With Tito Fojo?

Tito Fojo's AcademicInfluence.com Rankings